Egis favipiravir drug licenced for Covid-19 treatment
A new drug with the active ingredient favipiravir manufactured by Hungarian pharmaceutical company Egis has been licenced for treatment of Covid-19 by the National Institute of Pharmacy and Nutrition (OGYEI), the institute said on Saturday.
The licence was issued in an expedited procedure.
The drug, which Egis started developing in April, could be used to treat coronavirus patients from mid-January.
Favipiravir is the second drug, after remdesivir, that has been licenced by the OGYEI to treat Covid-19 patients.
In India, 39 different pharma companies now manufacture favipiravir.
In Bangladesh, 8 different pharma companies now manufacture favipiravir.
In Turkey, 8 different pharma companies now manufacture favipiravir.
In China, 5 different pharma companies now manufacture favipiravir.
In Egypt, 4 different pharma companies now manufacture favipiravir.
In Russia, 3 different pharma companies now manufacture favipiravir.
The following nations have only 1 manufacturer of favipiravir:
Bolivia, Costa Rica, Hungary, Indonesia, Iran, Japan, Jordan, Kazakhstan, Nepal, Pakistan, the Philippines, Romania, Taiwan, Thailand, the Ukraine.
In addition, numerous nations have imported favipiravir for treating COVID-19 but have not manufactured it.
The news is not 100% correct. MEDITOP Pharmaceutical Ltd. is also manufacturer of Favipiravir tablets in Hungary.